US Bancorp DE Sells 612,949 Shares of Pfizer Inc. (NYSE:PFE)

US Bancorp DE lessened its stake in Pfizer Inc. (NYSE:PFE) by 7.9% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 7,157,655 shares of the biopharmaceutical company’s stock after selling 612,949 shares during the period. US Bancorp DE’s holdings in Pfizer were worth $206,069,000 at the end of the most recent quarter.

A number of other hedge funds have also added to or reduced their stakes in PFE. Carr Financial Group Corp increased its holdings in shares of Pfizer by 3.3% in the third quarter. Carr Financial Group Corp now owns 11,012 shares of the biopharmaceutical company’s stock worth $344,000 after purchasing an additional 355 shares during the last quarter. Advisor OS LLC increased its stake in Pfizer by 1.0% in the 4th quarter. Advisor OS LLC now owns 35,202 shares of the biopharmaceutical company’s stock worth $1,013,000 after acquiring an additional 365 shares during the last quarter. Safeguard Investment Advisory Group LLC raised its holdings in shares of Pfizer by 3.9% during the 4th quarter. Safeguard Investment Advisory Group LLC now owns 9,987 shares of the biopharmaceutical company’s stock worth $288,000 after acquiring an additional 371 shares in the last quarter. Cairn Investment Group Inc. boosted its position in shares of Pfizer by 5.4% during the 3rd quarter. Cairn Investment Group Inc. now owns 7,323 shares of the biopharmaceutical company’s stock valued at $243,000 after acquiring an additional 372 shares during the last quarter. Finally, Monetary Management Group Inc. increased its position in Pfizer by 1.0% in the third quarter. Monetary Management Group Inc. now owns 38,651 shares of the biopharmaceutical company’s stock worth $1,282,000 after purchasing an additional 375 shares during the last quarter. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Pfizer Trading Down 2.8 %

PFE stock traded down $0.84 during mid-day trading on Thursday, reaching $28.76. The company had a trading volume of 27,851,640 shares, compared to its average volume of 42,412,793. The firm has a 50 day moving average of $27.24 and a 200 day moving average of $27.97. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.05 and a quick ratio of 0.78. Pfizer Inc. has a 12 month low of $25.20 and a 12 month high of $40.37. The company has a market capitalization of $162.97 billion, a PE ratio of -480.75, a price-to-earnings-growth ratio of 1.11 and a beta of 0.63.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Wednesday, May 1st. The biopharmaceutical company reported $0.82 EPS for the quarter, topping the consensus estimate of $0.56 by $0.26. Pfizer had a positive return on equity of 8.64% and a negative net margin of 0.56%. The company had revenue of $14.88 billion for the quarter, compared to the consensus estimate of $13.87 billion. During the same period last year, the business posted $1.23 EPS. Pfizer’s quarterly revenue was down 19.5% on a year-over-year basis. On average, equities analysts predict that Pfizer Inc. will post 2.39 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 14th. Shareholders of record on Friday, May 10th will be issued a dividend of $0.42 per share. This represents a $1.68 annualized dividend and a yield of 5.84%. The ex-dividend date is Thursday, May 9th. Pfizer’s payout ratio is -2,799.53%.

Analyst Ratings Changes

A number of brokerages have commented on PFE. Argus cut shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd. Guggenheim initiated coverage on Pfizer in a research note on Friday, February 23rd. They set a “buy” rating and a $36.00 price objective on the stock. BMO Capital Markets restated an “outperform” rating and set a $36.00 price objective (up from $33.00) on shares of Pfizer in a research report on Thursday, May 2nd. Morgan Stanley boosted their target price on Pfizer from $28.00 to $29.00 and gave the company an “equal weight” rating in a research report on Thursday, May 2nd. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $45.00 price target on shares of Pfizer in a report on Monday, April 15th. Ten equities research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $35.86.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.